US4329466A - Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives - Google Patents
Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives Download PDFInfo
- Publication number
- US4329466A US4329466A US06/254,684 US25468481A US4329466A US 4329466 A US4329466 A US 4329466A US 25468481 A US25468481 A US 25468481A US 4329466 A US4329466 A US 4329466A
- Authority
- US
- United States
- Prior art keywords
- sub
- formula
- amino
- obt
- cal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
Definitions
- the present invention relates to novel nor-tropane derivatives and particularly novel 3-aroylamino and 3-heteroaroylamino nor-tropanes, substituted in position 8, a process for preparing same and their application in therapeutics.
- an aroyl nucleus polysubstituted by the following groups or atoms: dimethoxy-2,3; dimethoxy-3,5; trimethoxy-2,3,4; methoxy-2 dibromo-3,5 amino-4;
- A--CO-- represents the 2-amino 4-methoxy 5-pyrimidinyl carbonyl nucleus of formula: ##STR8##
- A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus
- A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus
- A--CO-- represents a 2-methoxy 4-amino 5-chloro benzoyl nucleus
- A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus.
- the present invention comprises of course as well the pharmaceutically acceptable mineral or organic acids addition salts of said compounds.
- the compounds of formula (I) are obtained by condensing, by the mixed anhydrides method, the acids of formula:
- A--CO-- has the same meanings as A--CO-- in formula (I), with the corresponding ⁇ -3-amino nor-tropanes of formula: ##STR12## in which R has the same meaning as in formula (I).
- the compounds of formula (IV) in which the couple (R 8 , R 9 ) assumes the following values: (OCH 3 , CH 3 ) and (OC 2 H 5 , C 2 H 5 ) are also new and are obtained by a 3-stage synthesis which consists in treating 2-amino 5-ethoxycarbonyl 4-hydroxy pyrimidine, in solution in a basic organic solvent, such as pyridine, with an acid anhydride (e.g. acetic anhydride), then in reacting the product thus obtained with a chlorinating agent preferably phosphorous oxychloride, and finally in causing to react on the resulting raw product, sodium methylate or ethylate, respectively in solution in methanol or ethanol.
- a basic organic solvent such as pyridine
- the compounds of formula (VII), which are new, are obtained by a two-stage synthesis consisting in treating the compound of formula (III) in which R represents the benzyl group, with acetyl chloride or ethyl chloroformiate, in a tetrahydrofurane medium and in the presence of an organic base such as pyridine or triethylamine, then in hydrogenolyzing the product obtained, for example in the presence of palladium on charcoal at 10% in an ethanol medium, at a temperature of 60° C. and at a pressure of 15 bars.
- This condensation is preferably carried out in accordance with a process identical to the one used for synthesis of the compounds of formula (III) where R is different from the benzyl group.
- the compound of formula (VIII), also new, is obtained by hydrogenolysis--preferably in an acid medium, in the presence of palladium on charcoal at 10%, at room temperature, at a pressure of 90 mbars and in an alcohol medium--of the compound of formula: ##STR20##
- This latter compound is prepared in accordance with the process described above for the preparation of the compounds of formula (I) [mixed anhydrides method] by condensing acid of formula: ##STR21## with the compound of formula (III) wherein R is a benzyl group.
- the acid addition salts of the compounds of formula (I) may be obtained by usual methods.
- the acid e.g. hydrochloric, oxalic, maleic or fumaric acid
- an appropriate solvent such as ethanol for example.
- mice were demonstrated on mice particularly by the test of antagonism to apomorphine straightening, carried out in accordance with the method described by G. GOURET et alia in J. Pharmacol. (Paris) 1973, 4, 341.
- ED 50 effective doses 50 obtained by intraperitoneal administration, in accordance with the above-mentioned test, of the derivatives of formula (I) and SULPIRIDE chosen as reference compound, are given in table IV below.
- mice Acute toxicity was studied on mice by intraperitoneal administration, and the estimated lethal dose in accordance with the method described by MILLER and THINTER Proc. Soc. Exper. Biol. Med. 1944, 57, 261, are also shown in table IV.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
There are disclosed nor-tropane derivatives substituted at the 3 position with aroylamino or heteroaroylamino and substituted at the 8 position with benzyl, substituted benzyl, 2-methyl thiophene, 3-methyl thiophene, 2-methyl furan or cyclohexylmethyl. The compounds are prepared by condensing the carboxylic acids corresponding to said aroyl or heteroaroyl group with the corresponding β-3-amino-8-substituted nor-tropanes. The compounds possess neuroleptic properties.
Description
This is a division of application Ser. No. 110,067 filed Jan. 7, 1980.
The present invention relates to novel nor-tropane derivatives and particularly novel 3-aroylamino and 3-heteroaroylamino nor-tropanes, substituted in position 8, a process for preparing same and their application in therapeutics.
These new derivatives comply more precisely with the formula: ##STR1## in which R represents:
either a benzyl nucleus, in which case A--CO-- designates:
a 5-pyrimidinyl carbonyl nucleus of formula: ##STR2##
an aroyl nucleus of formula: ##STR3## in which the pair (R1, R2) assumes any one of the following values: (CH3, H), (CH3, F), (CH3, NO2), (CH3, OH);
an aroyl nucleus of formula: ##STR4## in which the set (R3, R4, R5) assumes any one of the following values: (CH3, NH2, Br), (CH3, CH3 CONH, Br), (CH3, CF3 CONH, Br), (CH3, CH3 CONH, Cl), (CH3, CF3 CONH, Cl), (C2 H5, NH2, Br), (CH3, NH2, H), (CH3, CH3 O, CH3 O), (CH3, CH3 O, H);
an aroyl nucleus polysubstituted by the following groups or atoms: dimethoxy-2,3; dimethoxy-3,5; trimethoxy-2,3,4; methoxy-2 dibromo-3,5 amino-4;
or a benzyl nucleus monosubstituted in the meta position of formula: ##STR5## in which R6 represents a methyl or trifluoromethyl group or a halogen atom, in which case A--CO-- designates the 2-methoxy 4-amino 5-bromo benzoyl nucleus of formula: ##STR6##
or a benzyl nucleus monosubstituted in the para position of formula: ##STR7## in which R7 represents:
a methyl or methoxy group or an atom of bromine or chlorine, in which case A--CO-- represents the 2-amino 4-methoxy 5-pyrimidinyl carbonyl nucleus of formula: ##STR8##
a lower alkyl or a trifluoromethyl group or an atom of chlorine, bromine or fluorine, in which case A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus,
or a 3,4-dichloro benzyl group, a 2-methyl thiophene group ##STR9## or a 3-methyl thiophene group ##STR10## in which case A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus;
or a 2-methyl thiophene, a 3-methyl thiophene or a 2-methyl furane group ##STR11## in which case A--CO-- represents a 2-methoxy 4-amino 5-chloro benzoyl nucleus;
or a cyclohexylmethyl group, in which case A--CO-- represents a 2-methoxy 4-amino 5-bromo benzoyl nucleus.
It should be noted that in formula (I), the chain A--CO--NH is in the equatorial position and the nor-tropanes having such a substituent in the equatorial position will be called β in what follows.
The present invention comprises of course as well the pharmaceutically acceptable mineral or organic acids addition salts of said compounds.
The compounds of formula (I) are obtained by condensing, by the mixed anhydrides method, the acids of formula:
A--COOH (II)
in which A--CO-- has the same meanings as A--CO-- in formula (I), with the corresponding β-3-amino nor-tropanes of formula: ##STR12## in which R has the same meaning as in formula (I).
The compounds of formula (II) complying more precisely with the particular formula: ##STR13## in which R8 represents a methoxy or an ethoxy group, are new and are obtained by saponification of the compound of formula: ##STR14## in which R8 has the same meanings as in formula (IIa) and R9 represents a methyl or ethyl group.
The compounds of formula (IV) in which the couple (R8, R9) assumes the following values: (OCH3, CH3) and (OC2 H5, C2 H5) are also new and are obtained by a 3-stage synthesis which consists in treating 2-amino 5-ethoxycarbonyl 4-hydroxy pyrimidine, in solution in a basic organic solvent, such as pyridine, with an acid anhydride (e.g. acetic anhydride), then in reacting the product thus obtained with a chlorinating agent preferably phosphorous oxychloride, and finally in causing to react on the resulting raw product, sodium methylate or ethylate, respectively in solution in methanol or ethanol.
The compound of formula (III) in which R represents the benzyl group is new and results from the reduction, by means of sodium in amyl alcohol, of the oxime of N-benzyl nor-tropine-3 one of formula: ##STR15##
The compounds of formula (III) in which R has the same meanings as in formula (I), with the exception of the benzyl group, are also new and are obtained by a two-stage synthesis which consists in condensing cyclohexylmethyl chloride, 3,4-dichloro benzyl chloride, 2-chloromethyl thiophene, 3-chloromethyl thiophene, 2-chloromethyl furane or the chlorides of formulae: ##STR16## in which R6 and R7 have the same meanings as in formula (I), on the compounds of formula: ##STR17## in which R10 represents the methyl or ethoxy group, this condensation being preferably carried out at reflux in an organic solvent such as acetone, acetonitrile or DMF in the presence of potassium carbonate or triethylamine, then in hydrolyzing the acetyl or carbethoxy group.
The compounds of formula (VII), which are new, are obtained by a two-stage synthesis consisting in treating the compound of formula (III) in which R represents the benzyl group, with acetyl chloride or ethyl chloroformiate, in a tetrahydrofurane medium and in the presence of an organic base such as pyridine or triethylamine, then in hydrogenolyzing the product obtained, for example in the presence of palladium on charcoal at 10% in an ethanol medium, at a temperature of 60° C. and at a pressure of 15 bars.
The compounds of formula (I) where the motif A--CO-- represents the group of formula: ##STR18## and wherein R is different from the benzyl group, may also be obtained by condensation of the compounds of formula (VIa) with the compound of formula: ##STR19##
This condensation is preferably carried out in accordance with a process identical to the one used for synthesis of the compounds of formula (III) where R is different from the benzyl group.
Finally, the compound of formula (VIII), also new, is obtained by hydrogenolysis--preferably in an acid medium, in the presence of palladium on charcoal at 10%, at room temperature, at a pressure of 90 mbars and in an alcohol medium--of the compound of formula: ##STR20##
This latter compound is prepared in accordance with the process described above for the preparation of the compounds of formula (I) [mixed anhydrides method] by condensing acid of formula: ##STR21## with the compound of formula (III) wherein R is a benzyl group.
The acid addition salts of the compounds of formula (I) may be obtained by usual methods. For example the acid, e.g. hydrochloric, oxalic, maleic or fumaric acid, is added to the compounds of formula (I) in base form, in the presence of an appropriate solvent such as ethanol for example.
The following preparations are given by way of examples to illustrate the invention.
Code number: 19
To a solution of 8.35 g of 4-amino 5-bromo 2-methoxy benzoic acid (II) in 200 ml of tetrahydrofurane cooled to 0° C., were added 5.18 ml of triethylamine, then 3.5 ml of ethyl chloroformiate. After 45 minutes at 0° C., 8.6 g of β-3-amino N-parafluorobenzyl nor-tropane [(III), prepared as in example 5, code No. 103] were added and left to agitate for 3 hours. The solvent was evaporated, the residue taken up in methylene chloride, washed with carbonated water, then with water, dried on sodium sulfate, filtered and the solvent evaporated. The residue was crystallized in isopropylic ether. It was filtered and the precipitate obtained (12.9 g) was dissolved in 150 ml of ethanol; chlorhydric ethanol ≃6.5 N was added, the precipitate obtained was filtered, rinsed with ether on the filter and recrystallized in absolute alcohol. 5 g of the expected product were obtained.
Yield: 36%
Melting point: >265° C.
Molecular weight: 498.82
Empirical formula: C22 H26 BrClFN3 O2
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 52.97 5.25 8.42
Obtained (%) 52.91 4.93 8.26
______________________________________
By the same process, but from the corresponding reagents, the compounds of the formula (I) appearing in table I below were obtained.
TABLE I
__________________________________________________________________________
##STR22##
__________________________________________________________________________
Mel-
Molecu-
ting
Code Empirical lar point
No.
ACO R Form formula weight
(°C.)
__________________________________________________________________________
##STR23##
##STR24## maleate
C.sub.25 H.sub.31 N.sub.5 O.sub.6
497.54
217
8
##STR25##
##STR26## base C.sub.20 H.sub.24 ClN.sub.5 O.sub.2
401.89
185
9 "
##STR27## base C.sub.21 H.sub.27 N.sub.5 O.sub.3
397.47
180
10 "
##STR28## base C.sub.21 H.sub.27 N.sub.5 O.sub.2
381.47
178
16
##STR29##
##STR30## base C.sub.22 H.sub.26 BrN.sub.3 O.sub.2
444.36
209
19
##STR31##
##STR32## HCl C.sub.22 H.sub.26 BrClFN.sub.3 O.sub.2
498.82
>260
20 "
##STR33## Base C.sub.22 H.sub.25 Br.sub.2 N.sub.3
O.sub.2 523.26
223
21 "
##STR34## Base C.sub.23 H.sub.25 BrF.sub.3 N.sub.3
O.sub.2 529.36
165
22 "
##STR35## base C.sub.22 H.sub.25 BrClN.sub.3 O.sub.2
478.81
216
23 "
##STR36## " C.sub.23 H.sub.28 BrN.sub.3 O.sub.2
458.39
217
24 "
##STR37## " C.sub.23 H.sub.28 BrN.sub.3 O.sub.2
" 192
25 "
##STR38## Base C.sub.22 H.sub.25 BrClN.sub.3 O.sub.2
478.81
189
26 "
##STR39## base C.sub.22 H.sub.25 BrFN.sub.3 O.sub.2
462.35
167
27 "
##STR40## " C.sub.22 H.sub.25 Br.sub.2 N.sub.3
O.sub.2 523.26
204
28 "
##STR41## " C.sub.22 H.sub.24 BrCl.sub.2 N.sub.3
O.sub.2 513.26
193
29 "
##STR42## Base C.sub.20 H.sub.24 BrN.sub.3 O.sub.2
450.39
213
30 "
##STR43## base C.sub.24 H.sub.30 BrN.sub.3 O.sub.2
472.41
182
32 "
##STR44## " C.sub.20 H.sub.24 BrN.sub.3 O.sub. 2
450.39
220
33 "
##STR45## Base C.sub.23 H.sub.25 BrF.sub.3 N.sub.3
O.sub.2 512.36
201
35 "
##STR46## Maleate + 4/5 H.sub.2 O
C.sub.26 H.sub.36 BrN.sub.3 O.sub.6 +
4/5 H.sub.2 O
566.48
160
37
##STR47##
##STR48## HCl C.sub.20 H.sub.25 BrClN.sub.5 O.sub.2
482.81
230
40
##STR49##
##STR50## HCl + 1/6 H.sub.2 O
C.sub.24 H.sub.29 BrClN.sub.3 O.sub.3 +
/6 H.sub.2 O
543.88
217
41
##STR51## " Base C.sub.24 H.sub.25 BrF.sub.3 N.sub.3
O.sub.3 540.37
191
42
##STR52## " " C.sub.24 H.sub.28 ClN.sub.3 O.sub.3
441.94
180
43
##STR53## " base C.sub.24 H.sub.25 ClF.sub.3 N.sub.3
O.sub.3 495.92
181
48
##STR54## " " C.sub.22 H.sub.25 N.sub.3 O.sub.4
395.44
138
49
##STR55## " Base C.sub.22 H.sub.25 N.sub.2 FO.sub.2
368.44
96
51
##STR56## " " C.sub.22 H.sub.26 N.sub.2 O.sub.3
366.44
195
60
##STR57## " base C.sub.24 H.sub.30 N.sub.2 O.sub.4
410.49
130
61
##STR58## " HCl + 3/5 H.sub.2 O
C.sub.24 H.sub.31 ClN.sub.4 O.sub.2 +
3/5 H.sub.2 O
457.77
220
62
##STR59## " HCl + 1/5 H.sub.2 O
C.sub.22 H.sub.27 ClN.sub.2 O.sub.2 +
1/5 H.sub.2 O
390.51
>260
64
##STR60## " Base + 2/3 H.sub.2 O
C.sub.23 H.sub.28 N.sub.2 O.sub.3 +
2/3 H.sub.2 O
392.48
78
67
##STR61## " base C.sub.22 H.sub.27 N.sub.3 O.sub.2
365.46
145
68
##STR62## " HCl C.sub.23 H.sub.29 ClN.sub.2 O.sub.3
416.93
209
71
##STR63##
##STR64## Base C.sub.20 H.sub.24 ClN.sub.3 O.sub.3
389.87
220
72 "
##STR65## " C.sub.20 H.sub.24 ClN.sub.3 O.sub.2
405.94
227
73 "
##STR66## Base C.sub.20 H.sub.24 ClN.sub.3 O.sub.2
405.94
215
74
##STR67##
##STR68## HCl + 1.2 H.sub.2 O
C.sub.22 H.sub.26 Br.sub.2 ClN.sub.3
O.sub.2 + 1.2 H.sub.2 O
581.35
208
75
##STR69## " fumarate
C.sub.27 H.sub.32 BrN.sub.3 O.sub.6
574.46
212
83
##STR70##
##STR71## base C.sub.23 H.sub.28 N.sub.2 O.sub.3
380.47
182
__________________________________________________________________________
ELEMENTARY
Code
Yield
ANALYSIS
No.
(%) % C H N
__________________________________________________________________________
3 62 Cal.
60.35
6.28
14.08
Obt.
60.08
6.25
14.13
8 62 Cal.
59.97
6.02
17.43
Obt.
59.69
6.00
17.35
9 65 Cal.
63.45
6.85
17.62
Obt.
63.66
7.10
17.66
10 71 Cal.
66.12
7.13
18.36
Obt.
66.20
7.15
78.31
16 65 Cal.
59.46
5.90
9.46
Obt.
59.37
6.00
9.66
19 36 Cal.
52.97
5.25
8.42
Obt.
52.91
4.93
8.26
20 67 Cal.
50.49
4.82
8.03
Obt.
50.68
4.67
7.86
21 72 Cal.
53.91
4.92
8.20
Obt.
53.85
4.68
8.05
22 70 Cal.
55.18
5.26
8.78
Obt.
55.12
5.24
8.86
23 71 Cal.
60.26
6.16
9.17
Obt.
60.44
6.13
9.27
24 64 Cal.
60.26
6.16
9.17
Obt.
60.28
6.41
9.23
25 58 Cal.
55.18
5.26
8.78
Obt.
55.48
5.11
8.77
26 55 Cal.
57.15
5.45
9.09
Obt.
57.43
5.29
9.01
27 78 Cal.
50.49
4.82
8.03
Obt.
50.58
4.79
8.27
28 76 Cal.
51.48
4.71
8.19
Obt.
51.67
4.77
8.40
29 54 Cal.
53.33
5.37
9.33
Obt.
53.15
5.26
9.40
30 81 Cal.
61.01
6.40
8.90
Obt.
60.92
6.45
8.98
32 67 Cal.
53.33
5.37
9.33
Obt.
53.40
5.44
9.31
33 58 Cal.
53.92
4.92
8.20
Obt.
53.74
4.93
8.33
35 48 Cal.
53.76
6.52
7.23
Obt.
53.50
6.16
7.33
37 51 Cal.
49.75
5.22
14.51
Obt.
49.56
5.15
14.58
40 54 Cal.
52.99
5.81
7.73
Obt.
53.25
5.61
7.76
41 90 Cal.
53.34
4.66
7.78
Obt.
53.64
4.92
7.92
42 63 Cal.
65.22
6.39
9.51
Obt.
64.99
6.69
9.34
43 63 Cal.
58.12
5.08
8.47
Obt.
58.35
5.35
8.60
48 77 Cal.
66.82
6.37
10.63
Obt.
66.59
6.55
10.79
49 81 Cal.
71.71
6.84
7.60
Obt.
71.60
7.10
7.65
51 57 Cal.
72.10
7.15
7.65
Obt.
72.29
7.42
7.62
60 73 Cal.
70.22
7.37
6.82
Obt.
70.07
7.18
6.72
61 57 Cal.
62.97
7.09
6.12
Obt.
63.26
7.11
6.08
62 61 Cal.
68.29
7.03
7.24
Obt.
67.78
7.36
7.46
64 85 Cal.
70.38
7.50
7.14
Obt.
70.23
7.39
7.04
67 47 Cal.
72.30
7.45
11.50
Obt.
72.40
7.78
11.37
68 53 Cal.
66.25
7.01
6.72
Obt.
66.18
7.11
6.85
71 51 Cal.
61.61
6.21
10.78
Obt.
61.92
6.34
11.02
72 58 Cal.
59.17
5.96
10.35
Obt.
59.15
5.91
10.12
73 47 Cal.
59.17
5.96
10.35
Obt.
59.13
5.64
10.37
74 36 Cal.
45.45
4.92
7.23
Obt.
45.69
4.77
7.11
75 45 Cal.
56.45
5.62
7.32
Obt.
56.45
5.74
7.33
83 91 Cal.
72.60
7.42
7.36
Obt.
72.52
7.41
7.25
__________________________________________________________________________
Code number: 8
1st stage: β-3-[5-(2-amino 4-methoxy pyrimidinyl) carbonyl] amino nor-tropane (VIII)
A solution of 148.5 g of maleate of β-3-[5-(2-amino 4-methoxy 4-pyrimidinyl) carbonyl] amino N-benzyl nor-tropane [(I), obtained as in example 1, melting point 185° C., Empirical formula C20 H25 N5 O2 +1/6 H2 O, elementary analysis: Cal. (%)-C: 64.84-H: 6.89-N: 18.91: Obt. (%)-C: 64.62-H: 6.86-N: 19.35], in 1,500 ml of alcohol at 50% was hydrogenolyzed in an autoclave at room temperature and at a pressure of 90 mbars, in the presence of 25 g of palladium on charcoal at 10%. It was filtered, the solvent evaporated, the residue crystallized in acetone and recrystallized in alcohol at 90%. 120 g of the desired product were thus isolated.
Yield: 98%
Melting point: 220° C.
Molecular weight: 412.41
Empirical formula: C17 H25 N5 O6 +7/5 H2 O
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 48.69 6.01 16.98
Obtained (%) 48.97 6.19 16.84
______________________________________
2nd stage: β-3-[5-(2-amino 4-methoxy pyrimidinyl) carbonyl] amino N-parachlorobenzyl nor-tropane (I)
Code number: 8
To a solution of 7 g of succinate of the compound of formula (VIII) previously obtained in 100 ml of acetone were added 9.8 g of potassium carbonate, then 4.28 g of para-chlorobenzyl chloride. Then the mixture was heated to reflux for 39 hours, the solvent was evaporated, the residue was diluted in water and extracted with chloroform. It was dried on sodium sulfate, the solvent was evaporated, the residue was crystallized in isopropylic ether and recrystallized in normal butylic alcohol. 5 g of the expected product were thus obtained.
Yield: 70%
Melting point: 185° C.
Molecular weight: 401.89
Empirical formula: C20 H24 ClN5 O2
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 59.77 6.02 17.43
Obtained (%) 59.69 6.00 17.35
______________________________________
By the same process, but from the corresponding reagents, the compounds of formula (I) appearing in table I and having code numbers 9, 10, 12 and 37 were obtained.
Code number: 88
1st stage: 2-amino 4-methoxy 5-methoxycarbonyl pyrimidine (IV)
Code number: 96
50 g of 2-amino 4-hydroxy 5-ethoxycarbonyl pyrimidine were heated to reflux with 40 ml of acetic anhydride in 300 ml of anhydrous pyridine for 2 hours. The reaction medium was then frozen, the precipitate filtered, rinced with acetone and dried. 140 g of the raw product thus obtained (yield 62%) was heated to 60° C. in 900 ml of phosphorous oxychloride for 2 hours. After cooling, 200 ml of ethyl ether were added while stirring; the precipitate formed was then filtered, rinced with ether, then thrown on 1 kg of ice and neutralised with a solution of sodium bicarbonate while stirring. The precipitate was filtered, rinced with water and dried. 112 g of this intermediate (yield 81%) were stirred for 2 hours in a solution of sodium methanolate at 0° C., prepared with 46 g of sodium in 800 ml of anhydrous methanol. Once again at the normal temperature, the precipitate was filtered, rinced with water and dried. 80 g of 2-amino 4-methoxy 5-methoxycarbonyl pyrimidine were obtained.
Yield: 95%
Melting point: 221° C. (Bu OH)
Empirical formula: C7 H10 ClN3 O3
Molecular weight: 219.631
Melting point: 260° C.
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 38.28 4.59 19.13
Obtained (%) 38.28 4.42 19.39
______________________________________
By the same process, but from the corresponding reagents, the compound of formula (IV) bearing the code number 97: 2-amino 4-ethoxy 5-ethoxycarbonyl pyrimidine was prepared.
Empirical formula: C9 H13 N3 O3
Molecular weight: 211.218
Melting point: 190° C. (Bu OH)
NMR (DMSO): δppm
2 triplets centred at 1.3 ppm 6 H (OCH2 --CH3)
2 quadruplets centered at 4.3 ppm 4 H (O--CH2 --)
1 group centered at 7.2 ppm 2 H (NH2)
1 singleton centered at 8.5 ppm 1 H (heteroatomic)
IR (KBr): γcm-1 3370 cm-1 (NH2)
1680 cm-1 ester (COO--C2 H5)
2nd stage: 5-(2-amino 4-methoxy pyrimidinyl)carboxylic acid (IIa)
Code number: 88
600 g of 2-amino 4-methoxy 5-methoxycarbonyl pyrimidine prepared in the preceding stage were heated to 65° C. with agitation for 1 hour in a mixture of 1.5 l of methanol and 1.5 l of NaOH at 5%. Once cooled, the reaction medium was poured on 4 l of iced water then acidifed to pH=3 under stirring with concentrated hydrochloric acid. The 5-(2-amino 4-methoxy pyrimidinyl) carboxylic acid precipitated, drained, washed with acetone then dried was obtained with a yield of 88.5%.
Empirical formula: C6 H6 N3 O3 Na, 1.25 H2 O
Molecular weight: 213.810
Melting point: 260° C.
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 33.73 4.01 19.67
Obtained (%) 34.05 3.73 19.84
______________________________________
By the same process, but from the corresponding reagents, the compound of formula (IIa) appearing in table II and bearing code number 89, is obtained.
TABLE II
__________________________________________________________________________
##STR72##
Mel-
Mole-
ting
Code
For- Empirical
cular
point
Yield
Elementary analysis - NMR spectrum -
No.
mula
R.sub.8
R.sub.9
formula weight
(°C.)
(%) IR spectrum - Thin layer
__________________________________________________________________________
chromatography
% C H N
88 IIa
OCH.sub.3
-- C.sub.6 H.sub.6 N.sub.3 O.sub.3 Na
213.81
260
88.5
Cal. 33.73
4.01 19.67
+ 1.25 H.sub.2 O Obt. 34.05
3.73 19.84
(sodium salt)
89 " OC.sub.2 H.sub.5
-- C.sub.7 H.sub.9 N.sub.3 O.sub.3
183.17
280
76 NMR spectrum (CF.sub.3 COOH) δ ppm
= 4.75; q; and 1.50; t:
OCH.sub.2CH.sub.3
7.5; m; NH.sub.2
8.8; s; (H at 6)
% C H N
96 IV OCH.sub.3
CH.sub.3
C.sub.7 H.sub.10 ClN.sub.3 O.sub.3
219.63
260
95 Cal. 38.28
4.59 19.13
(chlorhydrate) Obt. 38.28
4.42 19.39
97 " OC.sub.2 H.sub.5
C.sub.2 H.sub.5
C.sub.9 H.sub.13 N.sub.3 O.sub.3
211.22
190
92 NMR (DMSO) δ ppm
= 1.3; 2t; 6 H: 2 CH.sub.3
= 4.3; 2q; 4 H: 2 CH.sub.2
= 7.2; m; 2 H: NH.sub.2
= 8.5; s; 1 H at 6
IR (KBr) bands NH.sub.2 at 3370
cm.sup.-1
and COOC.sub.2 H.sub.5 at 1680
__________________________________________________________________________
cm.sup.-1.
Code number: 98
A suspension of 60 g of N-benzyl nor-tropane oxime (V) in 750 ml of amyl alcohol was heated to 40° C. and 50 g of sodium were introduced at a rate such that the temperature of the reaction mixture rose to 135°-140° C. Then the reaction medium was diluted with 300 ml of water, the organic phase was decanted, and extracted by means of 400 ml of HCl 6 N, and the aqueous phase was washed with isopropylic ether. Then, the aqueous phase was alkalized with concentrated potash, extracted with methylene chloride, dried on sodium sulfate, the solvent was evaporated and the residue distilled. 83 g yield 59%) of liquid, Eb0.15 =109°-111° C. was obtained which was added to an acetone solution of maleic acid. The precipitate obtained was filtered and recrystallized in absolute alcohol.
Melting point: 150° C.
Empirical formula: C22 H28 N2 O8 +4.5 H2 O
Molecular weight: 462.87
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 57.08 6.45 6.05
Obtained (%) 57.14 6.19 5.92
______________________________________
δppm=7.28, m, and 3.53, s, 7H (benzylic) centered on 3.17, m,: 2H (tropanic) at position 1 and 5 centered on 2.82, m,: 1H (tropanic) at position 3 1.52, s, 2 NH2 protons between 2.20 and 1.15, m, 8 tropanic protons (the displacement of the tropanic protons in the presence of Europium salt EU(FOD)3 and particularly of the proton at position 3, as well as the study of the value of the sum of the couplings of the multiplet signal of the proton at 3, in accordance with the law of KARPLUS, showed that proton -3 is at an axial position, this by analogy with the NMR spectra in the presence of Europium of the derivatives α and β-3-amino tropane).
Code number: 103
1st stage: β-3-acetamido nor-tropane (VII)
To a solution cooled to 0° C. of 96 g of β-3-amino N-benzyl nor-tropane [(III), code number 98, prepared in example 4] in 70 ml of triethylamine and 900 ml of tetrahydrofuran, were slowly added 28 ml of acetyl chloride. After 12 hours at room temperature 50 ml of water were added, the solvent was evaporated, the remaining aqueous phase was extracted with 200 ml of methylene chloride, washed with water, dried on sodium sulfate and the solvent was evaporated. 80 g of raw product were obtained which were dissolved in 1000 ml of alcohol. 1 ml of hydrochloric alcohol 5 N was added and the solution was hydrogenolyzed in the presence of 8 g of palladium on charcoal at 10% in an autoclave, at a temperature of 60° C. and a pressure of 15 bars. Then, it was filtered, the filtrate evaporated and the residue crystallized in ethyl acetate. 52 g of the expected product were thus obtained.
Yield: 77%
NMR spectrum (CDCl3): δppm=6.38, d, (J=7 Hz), amidic protons (--CO--NH--) (exchangeable) Centred on 4.18, m, 1 tropanic proton at 3 3.60, m, tropanic protons at 1 and 5 2.70, s, N--H proton (exchangeable) 1.96, s, 3 acetyl protons (CH3 CO--) between 2.20 and 1.15, m, 8 tropanic protons.
By the same process, but using ethyl chloroformiate (instead of acetyl chloride), β-3-ethoxycarbonylamino nor-tropane (VII) was obtained.
Melting point: 252° C.
Empirical formula: C10 H19 ClN2 O2
Molecular weight: 234.72
Elementary analysis:
______________________________________
C H N
______________________________________
Calculated (%) 51.17 8.16 11.94
Obtained (%) 50.98 8.05 11.98
______________________________________
NMR spectrum (CDCl3): δppm=
5.55, d, --NH--COO--
4.08, q, and 1.18, t, (J=7 Hz): --COOCH2 --CH3
1.96, s,: NH--
3.51, m, tropanic protons at 1 and 5
3.91, m, 1 tropanic proton at 3
centred on 1.72, m, tropanic protons at 2, 4, 6 and 7.
2nd stage: β-3-amino N-p-fluorobenzyl nor-tropane (III)
Code number: 103
A solution of 17 g of β-3-acetamido nor-tropane [(VII) obtained in the preceding stage], of 21 g of p-fluorobenzyl chloride and of 18 ml of triethylamine in 250 ml of acetone was heated to reflux for 12 hours. Then it was filtered, the filtrate was evaporated, and the residue was dissolved in 200 ml of methylene chloride, washed with water, dried on sodium sulfate and the solvent was evaporated. 21 g of raw product were obtained which was dissolved in 250 ml of sulphuric acid at 10% and the solution was heated to reflux for 24 hours. It was washed with 100 ml of methylene chloride, the aqueous solution was alkalized with concentrated potash, extracted with methylene chloride, dried on sodium sulfate and the solvent was evaporated. 17 g of raw product were obtained, yield 96%, which was used directly in the synthesis of the corresponding compound of formula (I) with code No. 19 and described in Example 1.
NMR spectrum (CDCl3): δppm=
centred on 7.08, m, and 3.52, s, 6H(benzylic)
centred on 3.15, m, tropanic protons at 1 and 5
centred on 2.94, m, 1 tropanic proton at 3
between 2.20 and 1.15, m, 8 tropanic protons
1.11, s, NH2 (exchangeable).
By the same process, but from β-3-ethoxycarbonylamino nor-tropane (VII) described in the preceding stage, the β-3-amino N-parafluorobenzyl nor-tropane (III) of code number 103 was also obtained.
By the same process, but from the corresponding reagents, the β-3-amino N-nor-tropanes of formula (III) were obtained. Apart from the few compounds of formula (III) given in table III, the majority of the compounds (III) were used raw (after checking by thin layer chromatography) in the synthesis of the corresponding compounds of formula (I).
TABLE III
__________________________________________________________________________
##STR73##
Mel-
Mole-
ting
Code Empirical
cular
point
Yield
Elementary analysis - NMR spectrum -
No.
R Form
formula weight
(°C.)
(%) IR spectrum
__________________________________________________________________________
Elementary analysis:
C H N
98
##STR74##
dimal- eate
C.sub.22 H.sub.28 N.sub.2 O.sub.8 + 4.5
462.872 O
150
59 Cal. (%) Obt. (%)
57.08 57.14
6.45 6.19
6.05 5.92
NMR (CDCl.sub.3) δ ppm = 7.32,
m, and 3.48, s,
99
##STR75##
base
C.sub.14 H.sub.19 BrN.sub.2
295.22
oil
63
##STR76##
= 3.15, m : H at 1 and 5
= 2.94, m : H at 3
between 2,20 and 1.25, m, H at
2,4,6 and 7,
= 1.10, s, NH.sub.2
NMR (CDCl.sub.3) δ ppm = 7.51,
m, and 3.59, s, 6H
100
##STR77##
" C.sub.15 H.sub.19 F.sub.3 N.sub.2
284.32
oil
71
##STR78##
= 3.15, m, H at 1 and 5;
= 2.92 : H at 3;between 2.20 and
1.15, m :
= H at 2,4,6 and 7
= 1.17, s, : NH.sub.2
NMR (CDCl.sub.3) δ ppm = 7.47,
m, and 3.58,s, 6H
101
##STR79##
" C.sub.14 H.sub.19 BrN.sub.2
295.22
oil
52
##STR80##
3.15, m, and 2.95, m, H at 1,3
and 5
= between 2.20 and 1.50, m, H at
2,4,6 and 7
= 1.42, s, : NH.sub.2
NMR (CDCl.sub.3) δ ppm = 7.10,
m, and 3.55,s, : 6H
102
##STR81##
" C.sub.14 H.sub.19 FN.sub.2
234.31
oil
66
##STR82##
= 3.15, m,and 2.94, m : H at 1,3
and 5
= between 2.20 and 1.18,m, H at
2,4,6 and 7
= 1.14, s, NH.sub.2
NMR (CDCl.sub.3) δ ppm =
7.08,m, and 3.52,s, : 6H
103
##STR83##
" C.sub.14 H.sub.19 FN.sub.2
234.31
oil
96
##STR84##
= 3.15,m : H at 1 and 5
= 2.94,m : H at 3
= between 2.20 and 1.15,m ; H at
2,4,6 and 7
= 1.11, s, : NH.sub.2
__________________________________________________________________________
The derivatives of formula (I) were tested on laboratory animals and showed neuroleptic properties.
These properties were demonstrated on mice particularly by the test of antagonism to apomorphine straightening, carried out in accordance with the method described by G. GOURET et alia in J. Pharmacol. (Paris) 1973, 4, 341.
The effective doses 50 (ED 50) obtained by intraperitoneal administration, in accordance with the above-mentioned test, of the derivatives of formula (I) and SULPIRIDE chosen as reference compound, are given in table IV below.
Acute toxicity was studied on mice by intraperitoneal administration, and the estimated lethal dose in accordance with the method described by MILLER and THINTER Proc. Soc. Exper. Biol. Med. 1944, 57, 261, are also shown in table IV.
TABLE IV
______________________________________
Tested Acute toxicity (mice
Amomorphine straightening
compound LD 50 mg/kg/i.p.)
ED 50 (mg/kg/i.p.)
______________________________________
SULPIRIE 170 37
3 300 0.04
8 220 0.035
9 240 0.01
10 325 0.035
16 240 0.01
19 90 0.010
20 >400 0.034
21 85 0.07
22 140 0.021
23 >400 0.07
24 160 0.05
25 100 0.03
26 140 0.011
27 >400 0.034
28 >400 0.12
29 180 0.012
30 230 0.3
32 140 0.05
33 >400 0.19
35 80 0.07
37 170 0.16
40 130 0.05
41 225 0.03
42 61 0.05
43 120 0.03
48 310 0.21
49 120 0.08
51 140 0.03
60 75 0.027
61 80 0.02
62 60 0.04
64 83 0.008
67 100 0.038
68 47 0.02
71 120 0.11
72 110 0.04
73 170 0.02
74 250 0.035
75 >400 0.021
83 140 0.031
______________________________________
As the results given in this table show, the difference between effective doses and lethal doses 50 is sufficient to allow the derivatives of formula (I) to be used in therapeutics.
These latter are particularly prescribed in the treatment of disturbances of the psychism.
They will be administered orally in the form of tablets, pills or capsules containing 50 to 300 mg of active ingredient (3 to 8 per day), in solution form containing 0.1 to 1% of active ingredient (10 to 40 drops once to thrice per day), by parenteral administration in the form of injectable ampoules containing 5 to 100 mg of active ingredient (3 to 8 ampoules per day).
Claims (7)
1. A compound having the formula ##STR85##
in which R and ACO are selected from the following combinations: 1. R is 2-methyl thiophene or 3-methyl thiopene, and ACO is 2-methoxy-4-amino-5-bromobenzoyl, and
2. R is 2-methyl thiophene, 3-methyl thiophene or 2-methyl furan, and ACO is 2-methoxy-4-amino-5-chlorobenzoyl,
and pharmacologically acceptable acid addition salts thereof.
2. A compound as claimed in claim 1 in which R is 2-methyl thiophene and ACO is 2-methoxy-4-amino-5-bromobenzoyl.
3. A compound as claimed in claim 1 in which R is 3-methyl thiophene and ACO is 2-methoxy-4-amino-5-bromobenzoyl.
4. A compound as claimed in claim 1 in which R is 2-methyl thiophene and ACO is 2-methoxy-4-amino-5-chlorobenzoyl.
5. A compound as claimed in claim 1 in which R is 3-methyl thiophene and ACO is 2-methoxy-4-amino-5-chlorobenzoyl.
6. A compound as claimed in claim 1 in which R is 2-methyl furan and ACO is 2-methoxy-4-amino-5-chlorobenzoyl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/254,684 US4329466A (en) | 1979-01-16 | 1981-04-16 | Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7900971 | 1979-01-16 | ||
| FR7900971A FR2446823A1 (en) | 1979-01-16 | 1979-01-16 | 3-Acylamino-8-arylmethyl-nortropane derivs. - useful as neuroleptic agents (NL 18.7.80) |
| FR7931656 | 1979-12-26 | ||
| FR7931656A FR2476088A2 (en) | 1979-01-16 | 1979-12-26 | NOVEL NOR-TROPANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| US06/254,684 US4329466A (en) | 1979-01-16 | 1981-04-16 | Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/110,067 Division US4471120A (en) | 1979-01-16 | 1980-01-07 | Nor-tropane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4329466A true US4329466A (en) | 1982-05-11 |
Family
ID=27250895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/254,684 Expired - Lifetime US4329466A (en) | 1979-01-16 | 1981-04-16 | Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4329466A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4471120A (en) * | 1979-01-16 | 1984-09-11 | Delalande S.A. | Nor-tropane derivatives |
| US20090258854A1 (en) * | 2008-04-11 | 2009-10-15 | Bacani Genesis M | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| US20100292208A1 (en) * | 2009-05-14 | 2010-11-18 | Genesis Bacani | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2838714A (en) * | 1953-09-28 | 1958-06-10 | Philips Corp | Igniting and operating circuit for discharge tubes |
-
1981
- 1981-04-16 US US06/254,684 patent/US4329466A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2838714A (en) * | 1953-09-28 | 1958-06-10 | Philips Corp | Igniting and operating circuit for discharge tubes |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4471120A (en) * | 1979-01-16 | 1984-09-11 | Delalande S.A. | Nor-tropane derivatives |
| US20090258854A1 (en) * | 2008-04-11 | 2009-10-15 | Bacani Genesis M | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| WO2009126806A2 (en) | 2008-04-11 | 2009-10-15 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase |
| US7939527B2 (en) | 2008-04-11 | 2011-05-10 | Janssen Pharmaceutica Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| EP2336125A1 (en) | 2008-04-11 | 2011-06-22 | Janssen Pharmaceutica N.V. | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| US20110159563A1 (en) * | 2008-04-11 | 2011-06-30 | Janssen Pharmaceutical Nv | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| US20110190503A1 (en) * | 2008-04-11 | 2011-08-04 | Janssen Pharmaceutical Nv | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| US8357684B2 (en) | 2008-04-11 | 2013-01-22 | Janssen Pharmaceutica Nv | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase |
| US20100292208A1 (en) * | 2009-05-14 | 2010-11-18 | Genesis Bacani | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
| WO2010132599A1 (en) | 2009-05-14 | 2010-11-18 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase |
| US8399465B2 (en) | 2009-05-14 | 2013-03-19 | Janssen Pharmaceutica Nv | Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene A4 hydrolase |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4536580A (en) | 4-Amino-5-bromo-2-methoxy-N-[8-(benzyl)]-8-azabicyclo[3.2.1]-3-YL-benzamide or a pharmacologically acceptable acid addition salt thereof | |
| US4321378A (en) | 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives | |
| US4434170A (en) | Nor-tropane derivatives, and their application in therapeutics | |
| US4656174A (en) | Quinoline therapeutic agents | |
| AU2004314287B2 (en) | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | |
| CA2166203C (en) | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]- 6-chloro-1,3-dihydro-indol-2-one | |
| AU635593B2 (en) | Azaoxindole derivatives | |
| HU220041B (en) | Fluoralkoxy substituted benzamide derivatives, process for producing them and pharmaceutical compositions containing them | |
| PL192411B1 (en) | Amidic derivatives and pharmaceutic composition containing such compounds | |
| US5712294A (en) | N-pyridyl carboxamides and derivatives | |
| MXPA06014337A (en) | Chromone derivatives useful as vanilloid antagonists. | |
| US4977165A (en) | Piperidine derivative and therapeutic and preventive agents for arrhythmia containing same | |
| US4914207A (en) | Arylthiazolylimidazoles | |
| SU1232145A3 (en) | Method of producing pyrimidine derivatives or pharmaceutically acceptable salts thereof | |
| KR20070043779A (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
| EP0181136B1 (en) | Oxindole antiinflammatory agents | |
| US4695571A (en) | Tricyclic oxindole antiinflammatory agents | |
| US5244894A (en) | 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics | |
| US5922871A (en) | Terephthalamide derivatives | |
| DE60022986T2 (en) | Pyridazin-3-one derivatives and medicines containing them | |
| US4624952A (en) | Pyridazine and pyrimidine compounds active on the central nervous system as sedatives or anticonvulsants | |
| US4329466A (en) | Certain nor-tropan-8-amine-3-aryl or heteroaryl derivatives | |
| US4424358A (en) | β-3-Amino nor-tropane compounds | |
| Ban et al. | Novel antiallergic agents. Part I: Synthesis and pharmacology of pyrimidine amide derivatives | |
| US4477450A (en) | Triazolo [4,3-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M185); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |